Hand-foot hyperpigmentation skin lesions associated with combination gemcitabine-carboplatin (GemCarbo) therapy

American Journal of Therapeutics

Volumn 18, Issue 6, 2011, Pages

  Kleynberg, Roman L ^a   Sofi, Aijaz A ^a   Chaudhary, Rekha T ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

chemotherapy side effects; gemcitabine carboplatinin therapy; hand foot hyperpigmentation

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CARBOPLATIN; GEMCITABINE; SALBUTAMOL;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COUGHING; DRUG WITHDRAWAL; HUMAN; HYPERPIGMENTATION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PAROXYSMAL DYSPNEA; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SKIN DISCOLORATION;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FOOT; HAND; HUMANS; HYPERPIGMENTATION; LUNG NEOPLASMS; MALE;

EID: 81755184742     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d860f6     Document Type: Article

References (14)

1. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine. Cancer Res. 1990;50: 4417-4422.
2. Bessis D, Guillot B, Legouffe E, et al. Gemcitabineassociated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51:73-76.
3. Green MR. Gemcitabine safety overview. Semin Oncol. 1996;23:32-35. (Pubitemid 26362192)
4. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1821-1826. (Pubitemid 24349383)
5. Kuku I, Kaya E, Sevinc A, et al. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma. J Eur Acad Dermatol Venereol. 2002;16:271-272. (Pubitemid 34785327)
6. Brandes A, Reichmann U, Plasswilm L, et al. Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine-a report of three cases. Anticancer Drugs. 2000;11:15-17. (Pubitemid 30166699)
7. del Pozo J, Martinez W, Yebra-Pimentel MT, et al. Linear immunoglobulin a bullous dermatosis induced by gemcitabine. Ann Pharmacother. 2001;35:891-893. (Pubitemid 32678715)
8. Cosar-Alas R, Yurut-Caloglu V, Karagol H, et al. Paraneoplastic syndrome of non-small cell lung carcinoma: a case with pancytopenia, leukocytoclastic vasculitis, and hypertrophic osteoarthropathy. Lung Cancer. 2007;56: 455-458. (Pubitemid 46679080)
9. OdehM,Misselevich I, Oliven A. Squamous cell carcinoma of the lung presenting with cutaneous leukocytoclastic vasculitis: a case report. Angiology. 2001;52: 641-644. (Pubitemid 32880115)
10. Marucci G, Sgarbanti E, Maestri A, et al. Gemcitabineassociated CD8+ CD30+ pseudolymphoma. Br J Dermatol. 2001;145:650-652.
11. Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol. 2006;33:86-97. (Pubitemid 43214489)
12. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer. 2005;15:13-18. (Pubitemid 40194327)
13. Bosch-Barrera J, Gaztañaga M, Ceballos J, et al. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie. 2009; 32:580-584.
14. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367-398. (Pubitemid 29115299)